We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+27.1%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$168M
AUM Growth
+$5.88M
Cap. Flow
-$6.82M
Cap. Flow %
-4.05%
Top 10 Hldgs %
44.13%
Holding
98
New
36
Increased
11
Reduced
15
Closed
33

Top Buys

1
AMAG
AMAG Pharmaceuticals
AMAG
+$4.08M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.7M
3
MMSI icon
Merit Medical Systems
MMSI
+$2.6M
4
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$2.51M
5
HSTO
Histogen Inc. Common Stock
HSTO
+$2.3M

Top Sells

1
GILD icon
Gilead Sciences
GILD
+$10.6M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$3.44M
3
SPNC
Spectranetics Corp
SPNC
+$3.42M
4
MZOR
Mazor Robotics Ltd.
MZOR
+$3.42M
5
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$3.34M

Sector Composition

1 Healthcare 44.95%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXTM
51
DELISTED
NxStage Medical Inc.
NXTM
$796K 0.47%
62,500
-62,500
-50% -$815K
ETRM
52
DELISTED
EnteroMedics Inc.
ETRM
$728K 0.43%
+381
New +$902K
BIOL
53
DELISTED
Biolase, Inc.
BIOL
$723K 0.43%
+24
New +$837K
FLXN
54
DELISTED
Flexion Therapeutics, Inc.
FLXN
$658K 0.39%
+40,000
New +$691K
RVNC
55
DELISTED
Revance Therapeutics, Inc.
RVNC
$630K 0.37%
+20,000
New +$625K
AMRN
56
Amarin Corp
AMRN
$292M
$543K 0.32%
+15,000
New +$558K
NVAX icon
57
Novavax
NVAX
$1.35B
$453K 0.27%
+5,000
New +$559K
CPRX icon
58
Catalyst Pharmaceutical
CPRX
$452K 0.27%
200,000
+25,000
+14% +$52.3K
DVAX
59
DELISTED
Dynavax Technologies
DVAX
$447K 0.27%
24,734
-10,266
-29% -$190K
ANAC
60
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$400K 0.24%
+20,000
New +$388K
SRNE
61
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$385K 0.23%
+30,000
New +$332K
DRRX
62
DELISTED
DURECT Corp
DRRX
$333K 0.2%
+25,000
New +$436K
RXDX
63
DELISTED
Ignyta, Inc.
RXDX
$195K 0.12%
+23,500
New +$220K
A icon
64
Agilent Technologies
A
$37.1B
– –
-20,970
Closed -$858K
BMRN icon
65
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-20,000
Closed -$1.41M
EW icon
66
CALL
Edwards Lifesciences
EW
$49.4B
– –
-600,000
Closed -$6.58M
GERN icon
67
Geron
GERN
$924M
– –
-248,630
Closed -$1.11M
GILD icon
68
Gilead Sciences
GILD
$167B
– –
-135,000
Closed -$10.6M
GILD icon
69
PUT
Gilead Sciences
GILD
$167B
– –
-750,000
Closed -$5.63M
HOLX
70
CALL
DELISTED
Hologic
HOLX
– –
-100,000
Closed -$2.23M
HOLX
71
DELISTED
Hologic
HOLX
– –
-65,000
Closed -$1.45M
JAZZ icon
72
Jazz Pharmaceuticals
JAZZ
$15.5B
– –
-10,000
Closed -$1.27M
MASI
73
DELISTED
Masimo
MASI
– –
-35,000
Closed -$1.02M
OSUR icon
74
OraSure Technologies
OSUR
$266M
– –
-200,000
Closed -$1.26M
QDEL icon
75
QuidelOrtho
QDEL
$1.19B
– –
-85,000
Closed -$2.63M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Ghost Tree Capital held 98 positions worth $168M, up 3.6% from $163M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital withdrew a net $6.82M in Q1 2014, closing 33 positions and reducing 15 holdings. Its most notable exit was Gilead Sciences, an estimated $10.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 50% a quarter earlier, followed by Technology.

Against the trend, Ghost Tree Capital opened a new position in AMAG Pharmaceuticals worth $3.72M.

  • Ghost Tree Capital's largest Q1 2014 buy was AMAG Pharmaceuticals: 192,057 shares worth $3.72M.
  • Ghost Tree Capital added most to CHELSEA THERAPEUTICS INT'L LTD in Q1 2014, an estimated $2.51M increase.
  • Ghost Tree Capital's biggest Q1 2014 reduction was Spectranetics Corp, cutting an estimated $3.42M.
  • Ghost Tree Capital fully exited Gilead Sciences in Q1 2014, selling an estimated $10.6M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $168M portfolio in Q1 2014.
  • Ghost Tree Capital opened 36 new positions and closed 33 in Q1 2014.
  • Ghost Tree Capital's portfolio value rose 3.6% quarter-over-quarter to $168M.

Based on Ghost Tree Capital's 13F filing for Q1 2014, filed 15 May 2014.